Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 16/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.65 |
| ▸ | HTR2A | P28223 | 4/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5229032 | 1.00 | MCHR1 (0.65) | MCHR1CHRM1HTR2ACYP2D6GRM5 | |
| SCHEMBL6366162 | 1.00 | MCHR1 (0.65) | MCHR1CHRM1HTR2ACYP2D6GRM5 | |
| SCHEMBL11492710 | 0.84 | HRH3 (0.48) | — | |
| SCHEMBL11492712 | 0.84 | HRH3 (0.48) | — | |
| SCHEMBL6373001 | 0.82 | MCHR1 (0.56) | MCHR1CHRM1HTR2ACYP2D6GRM5 | |
| SCHEMBL6372598 | 0.82 | MCHR1 (0.56) | MCHR1CHRM1HTR2ACYP2D6GRM5 | |
| SCHEMBL6372602 | 0.82 | MCHR1 (0.56) | MCHR1CHRM1HTR2ACYP2D6GRM5 | |
| SCHEMBL6372593 | 0.82 | MCHR1 (0.56) | MCHR1CHRM1HTR2ACYP2D6GRM5 | |
| SCHEMBL5228631 | 0.82 | MCHR1 (0.56) | MCHR1CHRM1HTR2ACYP2D6GRM5 | |
| SCHEMBL5229672 | 0.82 | MCHR1 (0.56) | MCHR1CHRM1HTR2ACYP2D6GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245529-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245529-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | MCHR1 1/4885CHRM1 49/4885HTR2A 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.